Tracheal intubation and direct laryngoscopy are considered as the most critical event during administration of general anaesthesia. Dexmedetomidine is an alfa-2 adrenergic agonist use for control of haemodynamic response to laryngoscopy and tracheal intubation. Our study consisted 60 patients of ASA grade I or II, scheduled for elective gynaecological, general and ENT surgery, divided into two groups of 30 patients each. Group A received injection dexmedetomidine 1.0 µg.kg-1 over 10 minutes and Group B received injection dexmedetomidine 0.5 µg.kg-1 over 5 min, both diluted in 10 ml normal saline. One min after dexmedetomidine, injection thiopental sodium 5 mg.kg -1 and injection vecuronium bromide 0.1 mg.kg -1 were administered intravenously for induction. Intubation was performed after 3 min. The parameters like heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and O2 saturation (SpO2) were recorded at pre-induction, 60 seconds (sec) after dexmedetomidine (t1), 60 sec after induction (t2), during laryngoscopy and tracheal intubation (t3), 1 min after intubation (t4), 2 min after intubation (t5) and 5 min after intubation (t6). Data obtained was analysed using unpaired t-test. We have observed statistically highly significant (p0.05). There were statistically highly significant (p0.05) at pre-induction, t1 and t2 in both groups. There was no significant changes in SpO2 in both groups at all intervals (p>0.05). We conclude that dexmedetomidine 1 µg.kg-1 is more effective than 0.5 µg.kg-1 in attenuating haemodynamic responses to laryngoscopy and tracheal intubation, without any systemic side effects.
Dexmedetomidine, endotracheal intubation, haemodynamic response, laryngoscopy